Vaxcyte Says Topline Results From OPUS Trial Expected In Q4 2026

Reuters
2025.12.08 12:35
Dec 8 (Reuters) - Vaxcyte Inc (PCVX.O) : * VAXCYTE DOSES FIRST PARTICIPANTS IN THE OPUS PHASE 3, NONINFERIORITY TRIAL EVALUATING VAX-31 FOR THE PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE AND PNEUMONIA IN ADULTS * VAXCYTE INC - TOPLINE RESULTS FROM OPUS TRIAL EXPECTED IN Q4 2026 Source text: Further company coverage: (PCVX.O)
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer